Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs) | BioSpace

[ad_1] — New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte’s PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Populations — — Expanded Collaboration Builds on Vaxcyte’s Current…

Moderna to cut mRNA drug substance production at Lonza facility

[ad_1] A bottle containing multiple doses of the Moderna COVID-19 vaccine is pictured at the Hausaerzte Hegibachplatz doctors office as the spread of the coronavirus disease (COVID-19) continues, in Zurich,…

Moderna, Switzerland’s Lonza strike deal on potential COVID-19 vaccine

[ad_1] The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 2, 2020. REUTERS/Arnd Wiegmann (Reuters) – Moderna Inc and Swiss contract drugmaker Lonza…

The Netherlands: Lonza adds ADC technology platform with Synaffix acquisition – LaingBuisson News

[ad_1] Basel Tower, Switzerland – Lonza Corporate Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has acquired Synaffix, a Dutch biotechnology company focused on commercializing its…

Lonza shortlists Lanxess, private equity in unit sale, sources say

[ad_1] FRANKFURT (Reuters) – Swiss contract drug maker Lonza has shortlisted German chemicals group Lanxess and private equity groups in the sale of its Lonza Specialty Ingredients (LSI) unit worth…